Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 20,000 shares at $45.05 ($895K) on 2025-03-17, disclosed to the SEC on 2025-03-18.
Scheduled sale ($895k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.70 | 8,201 | $367K | 40.9% |
| 2 | $44.70 | 8,201 | $367K | 40.9% |
| 3 | $45.05 | 1,799 | $81K | 9.1% |
| 4 | $45.05 | 1,799 | $81K | 9.1% |
| Total | $44.76 avg | 20,000 | $895K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |